Facebook Twitter LinkedIn Instagram Email Printer Google Plus

J. David Campbell

Partner, Health & Life Sciences, Oliver Wyman

As one of the fastest-rising categories of healthcare costs, pharmaceuticals need to develop a metric that explains pricing.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

Direct-purchase agreements are being floated as a price-control strategy. But how is value defined? And when might low cost come at the expense of true value?

Partner, Health & Life Sciences, Oliver Wyman
Senior Consultant, Oliver Wyman

The election results sent biopharma stock soaring. Breaking down what’s really on tap for biopharma over the next four years.

Partner, Health & Life Sciences, Oliver Wyman
Engagement Manager, Health & Life Sciences Practice, Oliver Wyman

Navigating the new checks-and-balances world of value-based pricing.

Partner, Health & Life Sciences, Oliver Wyman
Senior Consultant, Oliver Wyman

How a progressive GlaxoSmithKline (GSK) is leading the way in offering game-changing value-based pricing.

Partner, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

The Deal features David Campbell on how healthcare companies can leverage royalties, not their balance sheets, to fund innovation.

Partner, Health & Life Sciences, Oliver Wyman

Our Health & Life Sciences team returned from this year's annual JP Morgan Healthcare Conference in San Francisco with discussions around partnerships and consumerism particularly reverberating.

Partner, Health & Life Sciences, Oliver Wyman

Duke Royalty Limited, a Guernsey-based public diversified royalty company, and Oliver Wyman announced this week a financing collaboration in the rapidly developing pharmaceutical and healthcare-related royalty market.

Partner, Health & Life Sciences, Oliver Wyman

Last week Reuters reported that Novartis plans to use a novel pricing model when it launches its new heart failure drug Entresto. David Campbell, an Oliver Wyman Partner who specializes in valuing new drugs, breaks down how this new model could impact the traditional pharma-payer-provider dynamic.

Partner, Health & Life Sciences, Oliver Wyman